Fortescue Ltd
FMG
National Australia Bank Ltd
NAB
BHP Group Ltd
BHP
ANZ Group Holdings Ltd
ANZ
CommBank
CBA
AU Stock MarketDetailed Quotes
AGN Argenica Therapeutics Ltd
- 0.620
- -0.010-1.59%
20min DelayMarket Closed Jan 8 15:59 AET
79.42MMarket Cap-11.70P/E (Static)
0.640High0.620Low156.32KVolume0.640Open0.630Pre Close97.55KTurnover0.98552wk High0.17%Turnover Ratio128.09MShares0.51552wk Low-0.053EPS TTM56.75MFloat Cap1.020Historical HighLossP/E (Static)91.53MShs Float0.250Historical Low-0.053EPS LYR3.18%Amplitude--Dividend TTM5.69P/B1Lot Size--Div YieldTTM
Argenica Therapeutics Ltd News
Argenica Therapeutics Ltd: Phase 2 Stroke Clinical Trial Update
Argenica Therapeutics Ltd: $2.76m R&D Tax Incentive Cash Rebate Received for FY24
Argenica Therapeutics Ltd: Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
Argenica Therapeutics Ltd: FDA Grants ODD & RPDD for Second Drug in Treatment of HIE
Argenica Therapeutics Ltd: Argenica Appoints VP of Product Development
Argenica Therapeutics Ltd: Positive Results in Key IND Enabling Studies
Argenica Therapeutics Ltd: Initial Director's Interest Notice x2
Argenica Therapeutics Ltd: Date of AGM & Closing Date For Director Nominations
Argenica Therapeutics Ltd: Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
Argenica Therapeutics Ltd: Appendix 4G & Corporate Governance Statement
Argenica Therapeutics Ltd: Change of Director's Interest Notice
Argenica Therapeutics Ltd: Change of Director's Interest Notice x3
Argenica Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Argenica Therapeutics Ltd: Phase 2 Stroke Clinical Trial Update
Argenica Therapeutics Ltd: Investor Webinar Presentation
Argenica Therapeutics Ltd: Final Director's Interest Notice
Argenica Therapeutics Ltd: Change of Director's Interest Notice
Argenica Therapeutics Ltd: ARG-007 Reduces Effects of TBI in Preclinical Study
Argenica Therapeutics Ltd: DSMB Confirms Safety of First Patients Dosed
Argenica Therapeutics Ltd: Quarterly Activities/Appendix 4C Cash Flow Report